Yong Weon Yi

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 13

Top Venues

International journal of molecular sciences

Cancers

Life (Basel, Switzerland)

Pharmaceuticals (Basel, Switzerland)

ExoCoBio Inc.

This page only lists publications with an associated author ORCID identifier.

Affiliation History

ExoCoBio Inc.

South Korea

Director :: ExoCoBio Exosome Institute 2

ExoCoBio Inc. Jan 03 2017 - Dec 31 2018

South Korea

CTO / Managing Director :: ExoCoBio Exosome Institute

Logos Biosystems - Dec 31 2016

South Korea

Senior Scientist / Senior Manager

Logos Biosystems

South Korea

Senior Manager / Team Leader / Project Manager :: Biology R&D

Georgetown University - Jul 31 2014

United States

Research Specialist :: Department of Oncology, Lombardi Comprehensive Cancer Center

Publications

Yong Weon Yi
Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells. International journal of molecular sciences 24 (4) (2023)
Dong Joon Kim, Yong Weon Yi, Yeon Sun Seong
Beta-Transducin Repeats-Containing Proteins as an Anticancer Target. Cancers 15 (17) (2023)
Yong Weon Yi
Extracellular Vesicles as a New Therapeutic Entity. Life (Basel, Switzerland) 13 (6) (2023)
Yong Weon Yi
Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells. International journal of molecular sciences 24 (4) (2023)
Yong Weon Yi
Extracellular Vesicles as a New Therapeutic Entity. Life (Basel, Switzerland) 13 (6) (2023)
Yong Weon Yi
Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells. International journal of molecular sciences 24 (4) (2023)
Yong Weon Yi
Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells. International journal of molecular sciences 24 (4) (2023)
Yong Weon Yi, Kyu Sic You, Sanghee Han, In Jin Ha, Jeong-Soo Park, Seok-Geun Lee, Yeon Sun Seong
Inhibition of IκB Kinase Is a Potential Therapeutic Strategy to Circumvent Resistance to Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer Cells. Cancers 14 (21) (2022)
Kyu Sic You, Yong Weon Yi, Jeonghee Cho, Jeong-Soo Park, Yeon Sun Seong
Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. Pharmaceuticals (Basel, Switzerland) 14 (6) (2021)
Yong Weon Yi, Kyu Sic You, Jeong-Soo Park, Seok-Geun Lee, Yeon Sun Seong
Ribosomal Protein S6: A Potential Therapeutic Target against Cancer? International journal of molecular sciences 23 (1) (2021)
Kyu Sic You, Yong Weon Yi, Jeonghee Cho, Yeon-Sun Seong
Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells. Cancers 13 (6) (2021)
Dae Hyun Ha, Hyun-Keun Kim, Joon Lee, Hyuck Hoon Kwon, Gyeong-Hun Park, Steve Hoseong Yang, Jae Yoon Jung, Hosung Choi, Jun Ho Lee, Sumi Sung, Yong Weon Yi, Byong Seung Cho
Mesenchymal Stem/Stromal Cell-Derived Exosomes for Immunomodulatory Therapeutics and Skin Regeneration. Cells 9 (5) (2020)
Jun Ho Lee, Dae Hyun Ha, Hyeon-Kyu Go, Jinkwon Youn, Hyun-Keun Kim, Richard C Jin, Randy B Miller, Do-Hyung Kim, Byong Seung Cho, Yong Weon Yi
Reproducible Large-Scale Isolation of Exosomes from Adipose Tissue-Derived Mesenchymal Stem/Stromal Cells and Their Application in Acute Kidney Injury. International journal of molecular sciences 21 (13) (2020)

Yong Weon Yi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yong Weon Yi